Rivaroxaban with aspirin for the secondary prevention of cardiovascular events in Chinese patients with stable cardiovascular diseases: subgroup analysis of COMPASS.
10.3760/cma.j.cn112148-20210319-00247
- VernacularTitle:利伐沙班与阿司匹林联用在中国稳定性心血管疾病患者中的有效性及安全性评价：COMPASS研究中国亚组分析
- Author:
Yan LIANG
1
;
Ze Bin GONG
1
;
Ke Jia LOU
1
;
Li Sheng LIU
1
;
Jun ZHU
1
Author Information
1. Emergency and Intensive Care Center, Cardiovascular Department, Fuwai Hospital, Chinses Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.
- Publication Type:Randomized Controlled Trial
- MeSH:
Aged;
Aspirin/therapeutic use*;
Cardiovascular Diseases/prevention & control*;
China;
Drug Therapy, Combination;
Factor Xa Inhibitors/therapeutic use*;
Female;
Humans;
Male;
Middle Aged;
Platelet Aggregation Inhibitors/therapeutic use*;
Prospective Studies;
Rivaroxaban/therapeutic use*;
Secondary Prevention
- From:
Chinese Journal of Cardiology
2021;49(9):873-879
- CountryChina
- Language:Chinese
-
Abstract:
Objective: This analysis was performed to evaluate the efficacy and the safety of rivaroxaban-aspirin combination therapy in secondary prevention of major adverse cardiovascular events in Chinese patients enrolled in the COMPASS trial. Methods: COMPASS was a prospective, international multi-center and randomized controlled trial. From September 2014 to February 2017, 1 086 patients with stable coronary artery disease and peripheral artery diseases were recruited from 31 centers in China. Patients were randomly assigned to separately receive the therapy of rivaroxaban (2.5 mg twice a day) plus aspirin (100 mg once a day,) group (n=366), rivaroxaban (5 mg twice a day) alone group (n=365), and aspirin (100 mg once a day) alone group (n=355). Baseline information such as age, sex, etc. of all three groups was collected. Finally, 1 081 patients were followed up successfully, with the follow-up rate 99.5% and the average follow-up time was 19 months. The primary efficacy endpoint was the composite of cardiovascular death, myocardial infarction and stroke. The primary safety endpoint was major bleeding evaluated by modified International Society on Thrombosis and Haemostasis criteria. Results: Age of patients was (64.2±8.3) years and there were 293 male in rivaroxaban plus aspirin group. Age of patients was (63.8±9.0) years, and there were 301 male patients in rivaroxaban alone group. Age of patients was (63.6±8.8) years, and there were 282 male patients in the aspirin alone group. The incidences of primary efficacy endpoint occurred in 9 cases (1.5%) in rivaroxaban with aspirin group, 21 cases (3.7%) in rivaroxaban alone group and 14 cases (2.5%) in aspirin alone group. Meanwhile, the incidences of primary safety endpoint occurred in 6 cases (1.0%) in rivaroxaban with aspirin group, 9 cases (1.6%) in rivaroxaban alone group and 7 cases (1.2%) in aspirin alone group. The net clinical benefit events were 10 cases (1.7%) in rivaroxaban with aspirin group, 22 cases (3.9%) in rivaroxaban alone group and 15 cases (2.7%) in aspirin alone group (P>0.5%). Conclusions: The combination of rivaroxaban with aspirin can be safe and effectively used for the secondary prevention in Chinese patients with stable coronary artery disease and peripheral artery diseases.
